BioNexus Gene Lab Overview
Latest ROE for BioNexus Gene Lab: -33.11% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-33.11%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
BioNexus Gene Lab (BGLC) currently reports a ROE of -33.11%. That is below the sector sector average of -5.68%. Use the charts on this page to explore BioNexus Gene Lab's ROE history and peer comparisons.
BioNexus Gene Lab's ROE of -33.11% is lower than the its sector sector average of -5.68%. That is roughly 482.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but BioNexus Gene Lab's current -33.11% should be judged against industry norms (sector average: -5.68%) and against BGLC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -33.11%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is -5.68%. From there, open related valuation or income-statement pages for BioNexus Gene Lab, and consider following BGLC for alerts when major investors trade the stock.
